<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00956930</url>
  </required_header>
  <id_info>
    <org_study_id>STU 12339</org_study_id>
    <secondary_id>P30CA060553</secondary_id>
    <secondary_id>STU# 00012339</secondary_id>
    <secondary_id>CDR0000651416</secondary_id>
    <nct_id>NCT00956930</nct_id>
  </id_info>
  <brief_title>Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery</brief_title>
  <official_title>An Investigator Initiated Multicenter Prospective Randomized Study of Chemoembolization Versus Radioembolization for the Treatment of Hepatocellular Carcinoma (PREMIERE Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and
      keeping chemotherapy drugs near the tumor. Radioembolization kills tumor cells by blocking
      the blood flow to the tumor and keeping radioactive substances near the tumor. It is not yet
      known which treatment regimen is more effective in treating patients with liver cancer.

      PURPOSE: This randomized phase II trial is studying radioembolization to see how well it
      works compared with chemoembolization in treating patients with liver cancer that cannot be
      treated with Radiofrequency Ablation or removed by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare and contrast TACE and Y90 in order to determine either equivalence or
           superiority as measured by time-to-progression.

      Secondary

        -  Characterize the safety and toxicity profile of these regimens.

        -  Determine the need for subsequent treatment in these patients.

        -  Determine tumor response in these patients

        -  Characterize change in quality of life and functional status in these patients.

        -  Determine time to progression in these patients.

      OUTLINE: Patients are randomized to receive either TACE or Y90

        -  Arm I (radioembolization): Patients undergo radioembolization with yttrium Y 90 glass
           microspheres by hepatic artery infusion for approximately 1-3 courses.

        -  Arm II (transarterial chemoembolization [TACE]): Patients undergo TACE with mitomycin C,
           doxorubicin hydrochloride, and cisplatin by hepatic artery infusion for approximately
           1-3 courses.

        -  In both arms, treatment modifications may apply according to response.

      After completion of study treatment, patients are followed every 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">July 15, 2016</completion_date>
  <primary_completion_date type="Actual">June 2, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Progression (TTP) in Patients Treated With TACE and Y90</measure>
    <time_frame>Up to 6 yrs</time_frame>
    <description>Compare and contrast TACE and Y90 in order to determine either equivalence or superiority as measured by time-to-progression. Patients have repeat imaging done (MRI or CT) at 1-month post procedure and then every 3 months after that. TTP and overall survival (OS) analyses were calculated from day of randomization by Kaplan-Meier analysis on intention-to-treat (ITT) basis.
Progression (which is detected on follow-up imaging scans) was defined as:
Progression by World Health Organization (WHO) response criteria 25% increase in bidimensional cross product.
Progression by European Assosciation for the Study of the Liver (EASL): 25% increase in arterial enhancement
Malignant portal vein tumor thrombus development
Index lesion: lesions requiring re-treatment because of worsening circumferential enhancement
Development of new lesions or extra-hepatic metastases.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Achieved Complete or Partial Radiologic Response After Treatment</measure>
    <time_frame>up to 6 years</time_frame>
    <description>Repeat imaging (CT/MRI) and lab work including tumor markers will be assessed 1 month post-treatment then every 3 months after that. Both EASL &amp; WHO criteria are used.
By EASL criteria Complete response is 100% Decrease in amount of enhancing tissue in index lesion, Partial response is ≥50% deecrease in amount of enhancing tissue in index lesion, Stable disease is &lt;50% Decrease in to ≤ 25% increase in amount of enhancing tissue in index lesion, Progressive disease &lt;25% Increase in amount of enhancing tissue in index lesion and/or new enhancement in previously treated index lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From day of randomization until date of death, or liver transplant or 7/15/2016, whichever came first, assessed up to 6 years</time_frame>
    <description>Comparing overall survival of both treatment arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (radioembolization)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo radioembolization with yttrium Y 90 glass microspheres by hepatic artery infusion for approximately 1-3 courses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (transarterial chemoembolization [TACE])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo TACE with mitomycin C, doxorubicin hydrochloride, and cisplatin by hepatic artery infusion for approximately 1-3 courses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>yttrium Y 90 glass microspheres</intervention_name>
    <description>Patients undergo radioembolization.</description>
    <arm_group_label>Arm I (radioembolization)</arm_group_label>
    <other_name>Radioembolization</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>75mg fixed dose</description>
    <arm_group_label>Arm II (transarterial chemoembolization [TACE])</arm_group_label>
    <other_name>Doxorubicin hydrocholoride</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Chemoembolization (TACE)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Hepatocellular Carcinoma confined to the liver that is unresectable with surgery or
             unable to be treated with radiofrequency ablation diagnosed by biopsy or imaging
             criteria (CT/MRI)

          -  No segmental, lobar, or main portal vein thrombosis as evidenced by CT or MRI imaging

        Inclusion Criteria

          -  Adults &gt; 18 years old of either gender

          -  Diagnosis of liver confined HCC confirmed by histology or American Association for the
             Study of Liver Diseases (AASLD) guidelines [59,60] [appendix A].

          -  Lesions &lt; 1 cm in diameter have a low likelihood of being malignant and should be
             followed. Lack of growth over 1-2 years suggests it is not HCC.

          -  AFP &gt;200 and radiological evidence (arterial hypervascularity) of lesion &gt; 2 cm does
             not require biopsy.

          -  Two imaging modalities (triphasic CT, MRI, ultrasound, angiography) demonstrating
             &quot;arterial hypervascularity&quot; in the background of cirrhosis does not require biopsy

          -  One imaging modality with a lesion with arterial hypervascularity with wash out in
             early or delayed venous phase, does not require a biopsy

          -  Atypical appearances on imaging requires a biopsy.

          -  Non-conclusive biopsy requires closer monitoring

          -  For non-cirrhotics (by biopsy or imaging findings), diagnosis of HCC requires biopsy

          -  Patients with &lt;50% liver involvement

          -  Measurable liver confined disease with bi-dimensional measurements, required within 4
             weeks of screening. Lesions reported on imaging as &quot;too small to characterize&quot;,
             abdominal lymph nodes &lt; 2.0 cm or ascites in the setting of cirrhosis are not
             considered metastatic disease unless cytology proven.

          -  No segmental, lobar or main portal vein thrombosis as evidence by cross sectional
             imaging

          -  Prior resection permitted, no prior systemic, ablative or infusion therapy permitted

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 [appendix B]

          -  Childs score of A or B [appendix C]

          -  Required lab parameters within 28 days of screening

          -  Serum bilirubin ≤ 2.0 mg/dl (unless segmental infusion can be performed

          -  AST and ALT ≤ 5 times upper limit of normal (ULN)

          -  Creatinine ≤ 1.5 times ULN

          -  Prothrombin time (PT)/ International normalized ratio (INR) ≤ 2.3 or PT ≤ 6 seconds
             above control. If subjects are being anticoagulated they can participate if proof of
             no coagulation abnormality existed prior to use of anticoagulants

          -  Negative serum or urine pregnancy test for females of child bearing potential

          -  Ability to understand and sign the informed consent; patient must have signed informed
             consent prior to registration on study

          -  Women of childbearing potential and sexually active males must use contraception while
             on study

          -  Lesions must be treatable angiographically by either radioembolization or
             chemoembolization.

        Exclusion criteria

          -  Cardiac disease: Congestive heart failure &gt; class II New York Heart Association
             (NYHA). Patients must not have unstable angina (angina symptoms at rest) or new onset
             angina (began within the last 3 months) or myocardial infarction within the past 6
             months.

          -  Patients with infiltrative HCC are not eligible.

          -  Patients with bulk disease (≥70% tumor replacement of liver) are not eligible.

          -  Patients with ≥50% tumor replacement of liver, with an albumin &lt; 3.0 g/dl are not
             eligible.

          -  Major surgery within 4 weeks prior to the screening visit

          -  Active clinically serious infection &gt; Common Toxicity Criteria for Adverse Events
             (CTCAE v 4.0) Grade 2

          -  Any condition (psychological, physical or use/abuse of substances) which, in the
             opinion of the principal investigator (PI) or a sub-investigator (sub-I), would
             possibly endanger the subject during their participation in the study, or allow for
             non-compliance with the investigational drug and treatment under study.

          -  Due to the experimental nature of the therapy and the unknown risk to a fetus,
             pregnant and/or lactating women are not eligible to participate in this study.

          -  In the opinion of the investigator, patient is not a candidate/lesion not amenable for
             RFA (e.g. lesion location, shape, abnormal coagulation parameters, multi-focality).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Riad Salem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University, Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/27575820</url>
    <description>Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma</description>
  </link>
  <results_reference>
    <citation>Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, Mulcahy MF, Baker T, Abecassis M, Miller FH, Yaghmai V, Sato K, Desai K, Thornburg B, Benson AB, Rademaker A, Ganger D, Kulik L, Lewandowski RJ. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology. 2016 Dec;151(6):1155-1163.e2. doi: 10.1053/j.gastro.2016.08.029. Epub 2016 Aug 27.</citation>
    <PMID>27575820</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 8, 2009</study_first_submitted>
  <study_first_submitted_qc>August 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2009</study_first_posted>
  <results_first_submitted>April 11, 2018</results_first_submitted>
  <results_first_submitted_qc>September 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 1, 2019</results_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Riad Salem</investigator_full_name>
    <investigator_title>Chief Vascular and Interventional Radiology</investigator_title>
  </responsible_party>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be published in medical journals.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All BCLC stage HCC patients were reviewed by the multidisciplinary tumor board(transplant surgery, hepatology, medical oncology, and interventional radiology) between October 2009 and October 2015.</recruitment_details>
      <pre_assignment_details>179 patients BCLC A/B patients were eligible. 43 declined to participate, 29 selected other clinical trials, 49 requested Y90 and 13 requested cTACE. 45 agreed to be randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Radioembolization)</title>
          <description>Patients undergo radioembolization with yttrium Y 90 glass microspheres by hepatic artery infusion for approximately 1-3 courses.
yttrium Y 90 glass microspheres: Patients undergo radioembolization.</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Transarterial Chemoembolization [TACE])</title>
          <description>Patients undergo TACE with mitomycin C, doxorubicin hydrochloride, and cisplatin by hepatic artery infusion for approximately 1-3 courses.
Doxorubicin: 75mg fixed dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Radioembolization)</title>
          <description>Patients undergo radioembolization with yttrium Y 90 glass microspheres by hepatic artery infusion for approximately 1-3 courses.
yttrium Y 90 glass microspheres: Patients undergo radioembolization.</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Transarterial Chemoembolization [TACE])</title>
          <description>Patients undergo TACE with mitomycin C, doxorubicin hydrochloride, and cisplatin by hepatic artery infusion for approximately 1-3 courses.
Doxorubicin: 75mg fixed dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="58" upper_limit="65"/>
                    <measurement group_id="B2" value="64" lower_limit="62" upper_limit="70"/>
                    <measurement group_id="B3" value="64" lower_limit="58" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Progression (TTP) in Patients Treated With TACE and Y90</title>
        <description>Compare and contrast TACE and Y90 in order to determine either equivalence or superiority as measured by time-to-progression. Patients have repeat imaging done (MRI or CT) at 1-month post procedure and then every 3 months after that. TTP and overall survival (OS) analyses were calculated from day of randomization by Kaplan-Meier analysis on intention-to-treat (ITT) basis.
Progression (which is detected on follow-up imaging scans) was defined as:
Progression by World Health Organization (WHO) response criteria 25% increase in bidimensional cross product.
Progression by European Assosciation for the Study of the Liver (EASL): 25% increase in arterial enhancement
Malignant portal vein tumor thrombus development
Index lesion: lesions requiring re-treatment because of worsening circumferential enhancement
Development of new lesions or extra-hepatic metastases.</description>
        <time_frame>Up to 6 yrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Radioembolization)</title>
            <description>Patients undergo radioembolization with yttrium Y 90 glass microspheres by hepatic artery infusion for approximately 1-3 courses.
yttrium Y 90 glass microspheres: Patients undergo radioembolization.</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Transarterial Chemoembolization [TACE])</title>
            <description>Patients undergo TACE with mitomycin C, doxorubicin hydrochloride, and cisplatin by hepatic artery infusion for approximately 1-3 courses.
Doxorubicin: 75mg fixed dose</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression (TTP) in Patients Treated With TACE and Y90</title>
          <description>Compare and contrast TACE and Y90 in order to determine either equivalence or superiority as measured by time-to-progression. Patients have repeat imaging done (MRI or CT) at 1-month post procedure and then every 3 months after that. TTP and overall survival (OS) analyses were calculated from day of randomization by Kaplan-Meier analysis on intention-to-treat (ITT) basis.
Progression (which is detected on follow-up imaging scans) was defined as:
Progression by World Health Organization (WHO) response criteria 25% increase in bidimensional cross product.
Progression by European Assosciation for the Study of the Liver (EASL): 25% increase in arterial enhancement
Malignant portal vein tumor thrombus development
Index lesion: lesions requiring re-treatment because of worsening circumferential enhancement
Development of new lesions or extra-hepatic metastases.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="14.5" upper_limit="26"/>
                    <measurement group_id="O2" value="6.8" lower_limit="3.2" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.122</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.027</ci_lower_limit>
            <ci_upper_limit>0.557</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Achieved Complete or Partial Radiologic Response After Treatment</title>
        <description>Repeat imaging (CT/MRI) and lab work including tumor markers will be assessed 1 month post-treatment then every 3 months after that. Both EASL &amp; WHO criteria are used.
By EASL criteria Complete response is 100% Decrease in amount of enhancing tissue in index lesion, Partial response is ≥50% deecrease in amount of enhancing tissue in index lesion, Stable disease is &lt;50% Decrease in to ≤ 25% increase in amount of enhancing tissue in index lesion, Progressive disease &lt;25% Increase in amount of enhancing tissue in index lesion and/or new enhancement in previously treated index lesion.</description>
        <time_frame>up to 6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Radioembolization)</title>
            <description>Patients undergo radioembolization with yttrium Y 90 glass microspheres by hepatic artery infusion for approximately 1-3 courses.
yttrium Y 90 glass microspheres: Patients undergo radioembolization.</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Transarterial Chemoembolization [TACE])</title>
            <description>Patients undergo TACE with mitomycin C, doxorubicin hydrochloride, and cisplatin by hepatic artery infusion for approximately 1-3 courses.
Doxorubicin: 75mg fixed dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Achieved Complete or Partial Radiologic Response After Treatment</title>
          <description>Repeat imaging (CT/MRI) and lab work including tumor markers will be assessed 1 month post-treatment then every 3 months after that. Both EASL &amp; WHO criteria are used.
By EASL criteria Complete response is 100% Decrease in amount of enhancing tissue in index lesion, Partial response is ≥50% deecrease in amount of enhancing tissue in index lesion, Stable disease is &lt;50% Decrease in to ≤ 25% increase in amount of enhancing tissue in index lesion, Progressive disease &lt;25% Increase in amount of enhancing tissue in index lesion and/or new enhancement in previously treated index lesion.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete &amp; Partial Response Rate by EASL criteria</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease and progressive disease by EASL cri</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Comparing overall survival of both treatment arms.</description>
        <time_frame>From day of randomization until date of death, or liver transplant or 7/15/2016, whichever came first, assessed up to 6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Radioembolization)</title>
            <description>Patients undergo radioembolization with yttrium-90 glass microspheres by hepatic artery infusion for approximately 1-3 courses.</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Transarterial Chemoembolization [TACE])</title>
            <description>Patients undergo chemoembolization (TACE) with mitomycin C, doxorubicin hydrochloride, and cisplatin by hepatic artery infusion for approximately 1-3 courses.
Doxorubicin: 75mg fixed dose</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Comparing overall survival of both treatment arms.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" lower_limit="7.4" upper_limit="32.5"/>
                    <measurement group_id="O2" value="17.7" lower_limit="8.3" upper_limit="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The study period included patients treated between October 2009 and June 2016. Patients were followed-up date of treatment up to date of last imaging, death or study closure, approximately 6 years</time_frame>
      <desc>Pts were followed up to date of last imaging, death, study closure (6 years). SAEs were reported if pts developed grade 3 or higher. Non SAEs reported if &gt;1 pts developed grade 1-2. Two patients from arm II had follow-up at an outside hospital, both imaging and adverse-event related data were not available for us to include in the analyses. All efforts were made to obtain the data. Hence, they could not be included in the imaging/AE analysis. However, we were able to obtain survival status.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Radioembolization)</title>
          <description>Patients undergo radioembolization with yttrium-90 glass microspheres by hepatic artery infusion for approximately 1-3 courses.</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Transarterial Chemoembolization [TACE])</title>
          <description>Patients undergo chemoembolization (TACE) with mitomycin C, doxorubicin hydrochloride, and cisplatin by hepatic artery infusion for approximately 1-3 courses.
Doxorubicin: 75mg fixed dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>leukopenia</sub_title>
                <description>Grade 3 or 4 decrease in leukocyte count according to CTCAE (4.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Grade 3 or 4 neutropenia according to CTCAE (4.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Grade 3 or 4 vomiting according to CTCAE (4.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>Grade 3 or 4 anorexia according to CTCAE (4.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Grade 3 or 4 constipation according to CTCAE (4.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Grade 3 or 4 diarrhea according to CTCAE (4.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Grade 3 or 4 fatigue according to CTCAE (4.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Grade 3 or 4 Nausea according to CTCAE (4.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>Grade 3 or 4 fever according to CTCAE (4.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>Development of severe generalized infection (sepsis).</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <description>Grade 3 or 4 Abdominal Pain according to CTCAE V4.0</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <description>Grade 3 or 4 hypoalbuminemia according to CTCAE (4.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <description>Grade 3 or 4 bilirubin toxicity according to CTCAE (4.0)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase toxicity</sub_title>
                <description>Grade 3 or 4 alkaline phosphatase toxicity according to CTCAE (4.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase toxicity</sub_title>
                <description>Grade 3 or 4 alanine aminotransferase toxicity according to CTCAE (4.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase toxicity</sub_title>
                <description>Grade 3 or 4 aspartate aminotransferase toxicity according to CTCAE (4.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Liver Decompensation</sub_title>
                <description>Hepatic function deterioration due to treatment or decompensation due to preexisting hepatic cirrhosis</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <description>Grade 3 or higher hypokalemia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>cellulitis</sub_title>
                <description>Infection of cutaneous and subcutaneous tissue</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.04</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <description>Grade 1 or 2 leukopenia according to CTCAE (4.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Grade 1 or 2 neutropenia according to CTCAE (4.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Grade 1 or 2 vomiting according to CTCAE (4.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>Grade 1 or 2 anorexia according to CTCAE (4.0)</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Grade 1 or 2 Constipation according to CTCAE (4.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Grade 1 or 2 diarrhea according to CTCAE (4.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Grade 1 or 2 fatigue according to CTCAE (4.0)</description>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="24"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Grade 1 or 2 nausea according to CTCAE (4.0)</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>Grade 1 or 2 fever according to CTCAE (4.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <description>Grade 1 or 2 abdominal pain according to CTCAE (4.0)</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <description>Grade 1 or 2 hypoalbuminemia according to CTCAE (4.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Bilirubinemia</sub_title>
                <description>Grade 1 or 2 hyperbilirubinemia according to CTCAE (4.0)</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase toxicity</sub_title>
                <description>Grade 1 or 2 alkaline Phosphatase toxicity according to CTCAE (4.0)</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase toxicity</sub_title>
                <description>Grade 1 or 2 alanine aminotransferase toxicity according to CTCAE (4.0)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase toxicity</sub_title>
                <description>Grade 1 or 2 aspartate aminotransferase toxicity according to CTCAE (4.0)</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations include small sample size and required censoring of imaging/survival to transplant.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Riad Salem MD</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-695-6371</phone>
      <email>rsalem1@nm.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

